AT406771B - Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung - Google Patents

Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung Download PDF

Info

Publication number
AT406771B
AT406771B AT0902196A AT902196A AT406771B AT 406771 B AT406771 B AT 406771B AT 0902196 A AT0902196 A AT 0902196A AT 902196 A AT902196 A AT 902196A AT 406771 B AT406771 B AT 406771B
Authority
AT
Austria
Prior art keywords
crystal form
olanzapine
methyl
form according
benzodiazepine
Prior art date
Application number
AT0902196A
Other languages
German (de)
English (en)
Other versions
ATA902196A (de
Original Assignee
Lilly Co Eli
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT406771(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli, Lilly Industries Ltd filed Critical Lilly Co Eli
Publication of ATA902196A publication Critical patent/ATA902196A/de
Application granted granted Critical
Publication of AT406771B publication Critical patent/AT406771B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
AT0902196A 1995-03-24 1996-03-22 Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung AT406771B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24
PCT/US1996/003917 WO1996030375A1 (en) 1995-03-24 1996-03-22 Process and crystal forms of 2-methyl-thieno-benzodiazepine

Publications (2)

Publication Number Publication Date
ATA902196A ATA902196A (de) 2000-01-15
AT406771B true AT406771B (de) 2000-08-25

Family

ID=23621056

Family Applications (4)

Application Number Title Priority Date Filing Date
AT96302000T ATE204280T1 (de) 1995-03-24 1996-03-22 Kristallformen eines thieno(2,3-b)(1, 5)benzodiazepinderivates und verfahren zu deren herstellung
AT03077455T ATE331719T1 (de) 1995-03-24 1996-03-22 Verwendung von kristallformen von 2- methylthienobenzodiazepinen
AT0902196A AT406771B (de) 1995-03-24 1996-03-22 Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
AT00203573T ATE251627T1 (de) 1995-03-24 1996-03-22 Verfahren und kristallformen von 2- methylthienobenzodiazepinen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT96302000T ATE204280T1 (de) 1995-03-24 1996-03-22 Kristallformen eines thieno(2,3-b)(1, 5)benzodiazepinderivates und verfahren zu deren herstellung
AT03077455T ATE331719T1 (de) 1995-03-24 1996-03-22 Verwendung von kristallformen von 2- methylthienobenzodiazepinen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00203573T ATE251627T1 (de) 1995-03-24 1996-03-22 Verfahren und kristallformen von 2- methylthienobenzodiazepinen

Country Status (48)

Country Link
US (1) US5736541A (lt)
EP (3) EP1445259B1 (lt)
JP (1) JPH11502535A (lt)
KR (1) KR100399688B1 (lt)
CN (1) CN1065536C (lt)
AP (1) AP828A (lt)
AR (2) AR010448A1 (lt)
AT (4) ATE204280T1 (lt)
AU (1) AU706471B2 (lt)
BG (1) BG62619B1 (lt)
BR (1) BR9607790A (lt)
CA (1) CA2214005C (lt)
CH (1) CH690579A5 (lt)
CO (1) CO4650278A1 (lt)
CZ (1) CZ292688B6 (lt)
DE (4) DE69630324T2 (lt)
DK (4) DK0733635T3 (lt)
EA (1) EA000149B1 (lt)
EE (1) EE03489B1 (lt)
EG (1) EG23659A (lt)
ES (3) ES2159346T3 (lt)
FI (1) FI973750L (lt)
GB (1) GB2313835B (lt)
HU (1) HU224989B1 (lt)
IL (1) IL117610A (lt)
IS (1) IS1896B (lt)
LT (1) LT4349B (lt)
LU (1) LU90096B1 (lt)
LV (1) LV12018B (lt)
MY (1) MY114701A (lt)
NO (1) NO314663B1 (lt)
NZ (1) NZ306110A (lt)
OA (1) OA10510A (lt)
PA (1) PA8353701A1 (lt)
PE (1) PE44897A1 (lt)
PL (1) PL183723B1 (lt)
PT (3) PT1095941E (lt)
RO (1) RO118872B1 (lt)
SE (1) SE9703205L (lt)
SI (4) SI1445259T1 (lt)
SK (1) SK284143B6 (lt)
SV (1) SV1996000031A (lt)
TR (1) TR199701017T1 (lt)
TW (2) TW513432B (lt)
UA (1) UA44765C2 (lt)
WO (1) WO1996030375A1 (lt)
YU (1) YU49478B (lt)
ZA (2) ZA962344B (lt)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EP0852496A4 (en) * 1995-09-29 1998-11-11 Lilly Co Eli METHOD FOR TREATING CHRONIC ICT
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
CA2248758A1 (en) * 1996-03-11 1997-09-18 Pierre Van Tran Method for treating insomnia
JP2001517202A (ja) * 1996-03-25 2001-10-02 イーライ・リリー・アンド・カンパニー 痛み処置方法
CN1146421C (zh) * 1996-03-25 2004-04-21 伊莱利利公司 治疗疼痛的组合物以及药物在制备所述组合物中的应用
WO1997035582A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
WO1997035585A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Anesthetic method
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
TR199900639T2 (xx) * 1996-09-23 1999-06-21 Eli Lilly And Company Olanzapin dihidrat D.
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
AU6955998A (en) * 1997-04-15 1998-11-11 Eli Lilly And Company Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
PT1119359E (pt) * 1998-09-30 2004-08-31 Lilly Co Eli Formulacao de 2-metil-tieno-benzodiazepina
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
WO2001047933A1 (en) * 1999-12-28 2001-07-05 Cipla Limited New polymorphic forms of olanzapine
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
JP2004507548A (ja) * 2000-08-31 2004-03-11 ドクター・レディーズ・ラボラトリーズ・リミテッド オランザピン水和物の調製方法、及びこれを結晶形態のオランザピンに変換する方法
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
WO2003037903A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
US6906062B2 (en) 2001-12-24 2005-06-14 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-menthyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004000284A1 (en) * 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
CA2477088A1 (en) 2002-02-22 2003-10-02 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
SI1513846T1 (sl) 2002-05-31 2011-11-30 Sandoz Ag Postopek za pripravo olanzapina form I
SI21270A (sl) * 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
US20040242619A1 (en) * 2003-03-12 2004-12-02 Toth Zoltan G. Processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
AU2004291043A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
CA2551806A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries, Ltd. Methods of preparing olanzapine
EP1709053B1 (en) 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ES2253091B1 (es) * 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
EP1838716B1 (en) 2005-01-05 2011-06-01 Eli Lilly And Company Olanzapine pamoate dihydrate
CZ200563A3 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
EP1863775A4 (en) * 2005-03-21 2009-11-11 Reddys Lab Ltd Dr PROCESS FOR THE PREPARATION OF A CRYSTALLINE FORM I OF OLANZAPINE
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
CL2007002807A1 (es) * 2006-09-29 2008-04-11 Synthon Bv Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (en) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Process for the purification of olanzapine
HRP20240109T1 (hr) 2010-08-23 2024-03-29 Alkermes Pharma Ireland Limited Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
AU2013305895B2 (en) * 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
JP2025503013A (ja) 2022-01-20 2025-01-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー オランザピン、その組成物及びその使用方法
EP4554562B1 (en) 2023-01-10 2025-09-10 MedinCell SA Olanzapine compositions and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
IE53696B1 (en) 1981-12-02 1989-01-18 Wyeth John & Brother Ltd Solid shaped articles
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
DK0582368T3 (da) * 1992-05-29 2001-02-05 Lilly Co Eli Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents

Also Published As

Publication number Publication date
EA199700262A1 (ru) 1998-02-26
AR002719A1 (es) 1998-04-29
ZA962342B (en) 1997-09-22
LT97148A (lt) 1998-01-26
PT733635E (pt) 2001-12-28
KR100399688B1 (ko) 2004-02-18
YU17796A (sh) 1999-03-04
EE9700232A (et) 1998-04-15
SV1996000031A (es) 1998-03-27
ATA902196A (de) 2000-01-15
SI0733635T1 (en) 2002-06-30
EP1095941B1 (en) 2003-10-08
PT1095941E (pt) 2004-02-27
CZ292688B6 (cs) 2003-11-12
GB2313835B (en) 1998-09-16
DE69614426D1 (de) 2001-09-20
TR199701017T1 (xx) 1998-01-21
SI1095941T1 (en) 2003-12-31
EP1445259B1 (en) 2006-06-28
IL117610A (en) 2001-08-26
DE69630324D1 (de) 2003-11-13
EP1445259A1 (en) 2004-08-11
DE69614426T2 (de) 2002-05-23
CN1179160A (zh) 1998-04-15
SE9703205D0 (sv) 1997-09-05
DK1095941T3 (da) 2004-02-16
PL322501A1 (en) 1998-02-02
DK108997A (da) 1997-11-12
BR9607790A (pt) 1998-07-07
MX9707183A (es) 1997-11-29
ATE204280T1 (de) 2001-09-15
NZ306110A (en) 1998-09-24
DE69636313D1 (de) 2006-08-10
CH690579A5 (de) 2000-10-31
EE03489B1 (et) 2001-08-15
BG101900A (en) 1999-03-31
SI1445259T1 (sl) 2006-10-31
SK121897A3 (en) 1998-03-04
GB9719819D0 (en) 1997-11-19
SI9620040B (sl) 2002-02-28
EA000149B1 (ru) 1998-10-29
CA2214005A1 (en) 1996-10-03
HUP9802824A3 (en) 2000-01-28
ES2208220T3 (es) 2004-06-16
JPH11502535A (ja) 1999-03-02
PE44897A1 (es) 1997-10-22
HUP9802824A2 (hu) 1999-06-28
BG62619B1 (bg) 2000-03-31
LT4349B (lt) 1998-05-25
US5736541A (en) 1998-04-07
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
TW513432B (en) 2002-12-11
LV12018A (lv) 1998-04-20
MY114701A (en) 2002-12-31
ES2266719T3 (es) 2007-03-01
ES2159346T3 (es) 2001-10-01
LV12018B (en) 1998-09-20
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
DE19681286T1 (de) 1998-04-02
SK284143B6 (sk) 2004-10-05
DE69630324T2 (de) 2004-07-29
SI9620040A (sl) 1998-06-30
AU5427996A (en) 1996-10-16
CZ300097A3 (en) 1997-12-17
DE69636313T2 (de) 2007-05-31
CN1065536C (zh) 2001-05-09
CA2214005C (en) 2001-07-03
EP0733635A1 (en) 1996-09-25
EP0733635B1 (en) 2001-08-16
YU49478B (sh) 2006-05-25
CO4650278A1 (es) 1998-09-03
SE9703205L (sv) 1997-09-05
AP828A (en) 2000-04-28
ATE251627T1 (de) 2003-10-15
OA10510A (en) 2002-04-24
KR19980703188A (ko) 1998-10-15
NO974365L (no) 1997-09-22
RO118872B1 (ro) 2003-12-30
FI973750A0 (fi) 1997-09-22
IL117610A0 (en) 1996-07-23
AU706471B2 (en) 1999-06-17
NO314663B1 (no) 2003-04-28
PL183723B1 (pl) 2002-07-31
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
DK1445259T3 (da) 2006-10-16
HK1013988A1 (en) 1999-09-17
FI973750A7 (fi) 1997-09-22
ZA962344B (en) 1997-09-22
UA44765C2 (uk) 2002-03-15
DK0733635T3 (da) 2001-10-08
EG23659A (en) 2007-03-26
TW442488B (en) 2001-06-23
EP1095941A1 (en) 2001-05-02
LU90096B1 (fr) 1997-07-22
IS1896B (is) 2003-10-20
HU224989B1 (en) 2006-05-29
IS4564A (is) 1997-09-22
FI973750L (fi) 1997-09-22
GB2313835A (en) 1997-12-10
ATE331719T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
AT406771B (de) Neue kristalline form von 2-methyl-4-(4-methyl- 1-piperazinyl)-1oh-thieno (2,3-b) (1,5)-benzodiazepin, verfahren zu deren herstellung, pharmazeutische mittel und deren verwendung
DE69714165T2 (de) Olanzapindihydrat D
AT405606B (de) Orale olanzapin-formulierung
DE3143219C2 (lt)
DD267490A5 (de) Verfahren zur herstellung von wasserfreiem, kristallinem natriumsalz von 5-chlor-3-(2-thenoyl)-2-odindol-1-carboxamid
DE3443065C2 (lt)
EP1335720A1 (de) Sulfonamiden zur behandlung von erkrankungen des zentralen nervensystems
DE69630055T2 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
DE69527442T2 (de) Verfahren zur behandlung von wahrnehmungsstörungen
DE2060968A1 (de) Neue Thipyrane und Verfahren zu ihrer Herstellung
AT6739U1 (de) Neue polymorphe formen des olanzapins
DE69624566T2 (de) Behandlung der anorexie
DE10053799A1 (de) Verwendung von Tetrahydroisochinolinsulfonamiden
DE112005000641T5 (de) Neues Verfahren zur Herstellung einer pharmazeutisch reinen polymorphen Form I von Olanzapin
HK1013988B (en) Crystal forms of a thieno(2,3-b)(1,5) benzodiazepine derivative and process for their preparation
DE2157112B2 (de) Benzodiazepin-Derivat
DE19502792A1 (de) Neue Kristallmodifikation von Ketoprofenenantiomeren
DE10053795A1 (de) Neue Verwendung von Naphthalinsulfonamiden

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20140115